Daily Endocrinology Research Analysis
Three impactful endocrinology-related studies advance mechanistic understanding and therapeutic avenues across metabolic and endocrine complications. A Nature Communications study identifies G3BP1 as a key autophagy regulator in MASLD/MASH, a Diabetologia study shows acrolein scavenging preserves the retinal neurovascular unit in diabetic disease, and a FASEB Journal study demonstrates semaglutide slows ADPKD progression via metabolic reprogramming and mitochondrial effects.
Summary
Three impactful endocrinology-related studies advance mechanistic understanding and therapeutic avenues across metabolic and endocrine complications. A Nature Communications study identifies G3BP1 as a key autophagy regulator in MASLD/MASH, a Diabetologia study shows acrolein scavenging preserves the retinal neurovascular unit in diabetic disease, and a FASEB Journal study demonstrates semaglutide slows ADPKD progression via metabolic reprogramming and mitochondrial effects.
Research Themes
- Autophagy and lipid metabolism mechanisms in MASLD/MASH
- Neurovascular protection in diabetic retinal disease via acrolein scavenging
- Drug repurposing: GLP-1RA (semaglutide) for ADPKD through metabolic reprogramming
Selected Articles
1. Dysregulation of GTPase-activating protein-binding protein1 in the pathogenesis of metabolic dysfunction-associated steatotic liver disease.
This mechanistic study identifies reduced hepatic G3BP1 in human MASLD/MASH and shows that hepatocyte-specific loss of G3BP1 worsens steatosis and steatohepatitis in mice. G3BP1 directly facilitates autophagosome-lysosome fusion via STX17/VAMP8 and is required for TFE3 nuclear translocation, linking autophagy defects to increased lipogenesis.
Impact: Reveals a previously unrecognized autophagy nexus (G3BP1–STX17/VAMP8–TFE3) driving hepatic lipid accumulation, establishing a druggable node in MASLD/MASH pathogenesis.
Clinical Implications: While not practice-changing yet, the work nominates G3BP1 as a therapeutic target to restore autophagy and reduce hepatic lipogenesis; it also suggests biomarker development around G3BP1/TFE3 pathways.
Key Findings
- G3BP1 protein levels are reduced in livers from patients with MASLD/MASH.
- Hepatocyte-specific G3BP1 knockout male mice develop more severe MASLD/MASH phenotypes.
- G3BP1 promotes autophagosome-lysosome fusion via direct interaction with SNAREs STX17 and VAMP8; its loss causes autophagy dysfunction.
- G3BP1 is required for TFE3 nuclear translocation; G3BP1 loss enhances de novo lipogenesis.
Methodological Strengths
- Integration of human patient liver data with hepatocyte-specific knockout mouse models.
- Biochemical interaction mapping with SNARE proteins linking mechanism to phenotype.
Limitations
- Preclinical study without therapeutic rescue of G3BP1 function in vivo.
- Sex-limited mouse data (male mice emphasized) may limit generalizability.
Future Directions: Develop small molecules or biologics to modulate G3BP1-mediated autophagy and validate target engagement and efficacy in MASLD/MASH models, followed by translational biomarker studies.
Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are two common liver disorders characterized by abnormal lipid accumulation. Our study found reduced levels of GTPase-activating protein-binding protein1 (G3BP1) in patients with MASLD and MASH, suggesting its involvement in these liver disorders. Hepatocyte-specific G3BP1 knockout (G3BP1 HKO) male mice had more severe MASLD and MASH than their corresponding controls. Intriguingly, the G3BP1 HKO MASLD model male mice exhibit dysregulated autophagy, and biochemical analyses demonstrated that G3BP1 promotes autophagosome-lysosome fusion through direct interactions with the SNARE proteins STX17 and VAMP8. We also show that hepatic knockout of G3BP1 promotes de novo lipogenesis, and ultimately found that G3BP1 is required for the nuclear translocation of the well-known liver-lipid-regulating transcription factor TFE3. Taken together, our results suggest that G3BP1 should be investigated as a potential target for developing medical interventions to treat MASLD and MASH.
2. Scavenging acrolein with 2-HDP preserves neurovascular integrity in a rat model of diabetic retinal disease.
In diabetic rats, oral 2-HDP reduced acrolein-derived adducts (FDP-Lys), preserved neuroretinal function (ERG), and reduced vascular leakage and degeneration without affecting glycemia or weight. Human diabetic retinas also showed FDP-Lys accumulation, and simulations supported systemic delivery of 2-HDP.
Impact: Targets a non-glycemic driver of retinal neurovascular injury (acrolein adducts), demonstrating disease modification potential in DRD with translational evidence from human tissue and drug permeability modeling.
Clinical Implications: Suggests a novel adjunctive therapeutic strategy for diabetic retinal disease beyond glycemic control and anti-VEGF therapy; supports advancing 2-HDP to dose-finding and safety studies.
Key Findings
- 2-HDP did not alter blood glucose, body weight, or water intake but reduced acrolein adduct (FDP-Lys) accumulation.
- Neuroretinal function was preserved (ERG) and microvascular leakage (Evans Blue) and degeneration were reduced.
- Cytokine profiling indicated attenuation of diabetes-induced retinal inflammation with 2-HDP.
- FDP-Lys accumulation was confirmed in human diabetic retinas; molecular simulations support passive permeability and systemic delivery feasibility.
Methodological Strengths
- Comprehensive phenotyping across function (ERG), structure (SD-OCT), vascular leakage, histology, and cytokine arrays.
- Translation strengthened by human retinal analysis and computational chemistry for delivery.
Limitations
- Preclinical rat model; human efficacy and safety are untested.
- Abstract truncation precludes full reporting of systemic parameters; detailed dosing/toxicity not described.
Future Directions: Perform GLP/toxicology and dose-ranging studies, then initiate early-phase clinical trials with FDP-Lys as a pharmacodynamic biomarker.
AIMS/HYPOTHESIS: Diabetic retinal disease (DRD) is characterised by progressive neurovascular unit (NVU) dysfunction, often occurring before visible microvascular damage. Our previous studies suggested that the accumulation of acrolein (ACR)-derived protein adducts on retinal Müller cells and neuronal proteins may contribute to NVU dysfunction in diabetes, although this has yet to be directly tested. In this study, we evaluated the effects of the novel ACR-scavenging drug 2-hydrazino-4,6-dimethylpyrimidine (2-HDP) on retinal NVU dysfunction in experimental diabetes and explored its potential for systemic delivery in humans. METHODS: Sprague Dawley rats were divided into three groups: non-diabetic rats; streptozocin (STZ)-induced diabetic rats; and STZ-induced diabetic rats treated with 2-HDP in their drinking water throughout the duration of diabetes. Endpoint measures were taken at varying time points, ranging from 1 to 6 months post-diabetes induction. Retinal function and structure were evaluated using electroretinography (ERG) and spectral-domain optical coherence tomography (SD-OCT). Retinal vessel calibre, BP and vasopermeability (assessed by Evans Blue leakage) were also monitored. Immunohistochemistry was employed to assess retinal neurodegenerative and vasodegenerative changes, while cytokine arrays were used to investigate the effect of 2-HDP on diabetes-induced retinal inflammation. The accumulation of the ACR-protein adduct Nε-(3-formyl-3,4-dehydropiperidino)lysine (FDP-Lys) in human diabetic retinas was analysed. Computational chemistry simulations were performed to predict 2-HDP's passive permeability properties and its potential for systemic delivery. RESULTS: 2-HDP treatment had no effect on blood glucose, body weight, water intake, HbA CONCLUSIONS/INTERPRETATION: 2-HDP protects against retinal NVU dysfunction in diabetic rats by reducing FDP-Lys accumulation, preserving neuroretinal function and preventing microvascular damage, independent of glycaemic control. These results, combined with evidence from human diabetic retinas and molecular dynamics simulations, support 2-HDP's potential as a promising therapeutic agent for DRD, warranting further preclinical and clinical investigation.
3. GLP-1RA Semaglutide Delays the Progression of ADPKD Through Regulation of Glycolysis, Mitochondria Function and Ketosis.
Semaglutide slowed cyst growth in multiple Pkd1 mutant mouse models while reprogramming cellular metabolism (reduced glycolysis/ATP), suppressing proliferative and inflammatory signaling (Rb/S6/Stat3, NF-κB), normalizing mitochondrial structure/function, inducing apoptosis of mutant cells, promoting ketosis (↑β-hydroxybutyrate, AMPK activation), and reducing renal fibrosis.
Impact: Demonstrates a widely used GLP-1RA can modify ADPKD pathobiology through convergent metabolic and signaling mechanisms, providing a strong rationale for repurposing and clinical trials.
Clinical Implications: Supports investigating semaglutide as an adjunct or alternative to current ADPKD therapies in clinical trials; not practice-changing yet but suggests metabolic targeting may complement cyst-directed treatments.
Key Findings
- GLP-1R expression is decreased in Pkd1 mutant renal epithelial cells and kidneys.
- Semaglutide delays cyst growth in aggressive and long-lasting Pkd1 mutant mouse models.
- Semaglutide reduces glucose uptake, ATP generation, and glycolysis; suppresses Rb, S6, Stat3 and NF-κB signaling; normalizes mitochondrial morphology/function.
- Induces apoptosis of Pkd1 mutant cells, promotes ketosis with increased serum β-hydroxybutyrate and AMPK activation, and reduces renal fibrosis via TGF-β pathway deactivation.
Methodological Strengths
- Use of multiple Pkd1 mutant mouse models capturing aggressive and chronic disease courses.
- Mechanistically rich profiling across metabolism, signaling, mitochondrial biology, inflammation, cell death, and fibrosis with a clinically approved agent.
Limitations
- Preclinical models without human clinical data; dosing/exposure and long-term safety not delineated in the abstract.
- Reduced GLP-1R expression in mutant cells may influence translatability and requires human validation.
Future Directions: Initiate controlled clinical trials in ADPKD to assess renal endpoints and safety, optimize dosing, and explore biomarkers (β-hydroxybutyrate, AMPK activation) for response.
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease that is caused by mutations in PKD genes. Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are a class of medications that mimic the actions of the hormone GLP-1, conferring beneficial effects on weight management and other metabolic conditions. However, whether GLP-1RA plays a kidney-protective action in ADPKD remains unknown. In this study, we define the role and mechanisms of one of the most popular GLP-1RA agonists, Semaglutide, in ADPKD. We show that the expression of GLP-1R is decreased in Pkd1 mutant renal epithelial cells and kidneys. Treatment with Semaglutide delays cyst growth in aggressive and long-lasting Pkd1 mutant mouse models. Treatment with Semaglutide (1) decreases glucose uptake, ATP generation, and glycolysis, (2) deactivates PKD-associated signaling pathways, including Rb, S6, and Stat3, resulting in a decrease in cell proliferation, (3) deactivates NF-kB signaling pathways, resulting in a decrease in the expression of cytokines and the recruitment of macrophages, (4) normalizes mitochondrial morphology and function, (5) induces Pkd1 mutant renal epithelial cell death, (6) induces ketosis characterized by an increase in serum level of beta-hydroxybutyrate (BHB) and the activation of AMPK, and (7) alleviates renal fibrosis through deactivation of TGF-b signaling in Pkd1 mutant mouse kidneys. This study highlights the potential of GLP-1R agonists as a novel therapeutic strategy for ADPKD treatment.